title: Increased titres of IgM anti-heparan sulfate antibody in Behçet's disease.
abstract: OBJECTIVE
  Endothelial dysfunction is crucial in Behçet's disease (BD) pathogenesis, and measures of endothelial damage are potential markers of BD activity. Heparan sulfate (HS) is the most abundant proteoglycan in the endothelial cells, and anti-HS antibodies have been reported in subjects with vascular damage, due to vasculitis/vasculopathy. The aim of our study was to measure serum anti-HS antibodies in patients with BD and to determine whether their presence correlates with disease activity or clinical manifestations.
  
  
  METHODS
  Thirty-two patients with BD (21 men, 11 women) (median age 36.81+/-12.0 years) were considered. Of these, 13 had clinically active disease at the time of study. The mean disease duration was 7.31+/- 8.2 years (median 6 years). Anti-HS antibodies were measured by ELISA. As controls, sera from 40 sex- and age-matched healthy subjects, and 78 age-matched patients with systemic lupus erythematosus (SLE) were studied.
  
  
  RESULTS
  Anti-HS IgM antibody titres were significantly higher in BD patients compared to healthy subjects (p=0.016) and SLE controls (p=0.0008). No differences in anti-HS IgG antibody titres were observed among the 3 groups. Using categorical data, increased titres of IgM anti-HS antibodies were significantly more frequent in patients with BD vs patients with SLE (p=0.02). The presence of the antibodies, of either isotype, did not correlate with disease duration, disease activity or clinical manifestations.
  
  
  CONCLUSIONS
  BD patients have increased IgM anti-HS antibody titres compared to healthy and SLE controls. These antibodies did not correlate with disease activity or discrete clinical features, but might be relevant for pathogenic mechanisms of the disease.
authors.affiliation: Department of Neurosciences, University of Padova, Padova, Italy. chiara.briani@unipd.it
authors.forename: C
authors.initials: C
authors.lastname: Briani
authors.forename: A
authors.initials: A
authors.lastname: Doria
authors.forename: R
authors.initials: R
authors.lastname: Marcolongo
authors.forename: S
authors.initials: S
authors.lastname: Tognon
authors.forename: S
authors.initials: S
authors.lastname: Ruggero
authors.forename: E
authors.initials: E
authors.lastname: Toffanin
authors.forename: M
authors.initials: M
authors.lastname: Ermani
authors.forename: A
authors.initials: A
authors.lastname: Ghirardello
authors.forename: S
authors.initials: S
authors.lastname: Zampieri
authors.forename: G
authors.initials: G
authors.lastname: Semenzato
mesh_terms: D000328:Adult; D001528:Behcet Syndrome / Q000097:blood / Q000276:immunology* / Q000473:pathology; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006497:Heparan Sulfate / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index
chemical_list: D015415:Biomarkers; D006497:Heparan Sulfate; D007075:Immunoglobulin M